Drugmakers push Trump-friendly efforts as deadline to decrease costs nears
Pharmaceutical corporations are scrambling to make last-minute bulletins forward of a Trump administration deadline on Monday for the companies to decrease U.S. drug costs. But it surely’s not clear if the initiatives — which embrace investments within the U.S. and new direct-to-consumer fashions — will meet the president’s expectations.
President Trump in July despatched letters to 17 main pharma corporations, demanding that they take a number of actions to decrease U.S. drug costs in keeping with what different international locations pay as a part of his “most-favored nations” coverage.
Thus far, corporations have expressed the best enthusiasm for one of many calls for within the letters, specifically — that they implement direct-to-consumer fashions for his or her medication, with AstraZenca and Bristol Myers Squibb this week each saying new choices. This type of mannequin, which cuts out insurers and pharmacy profit managers, is welcomed by the administration however received’t fulfill Trump’s calls for except they decrease costs to ranges paid by different international locations, a White Home official instructed STAT, talking on the situation of anonymity.
This text is unique to STAT+ subscribers
Unlock this text — plus every day intelligence on Capitol Hill and the life sciences trade — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
